<DOC>
	<DOC>NCT00422383</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of various treatment and retreatment regimens of MabThera. All patients will receive concomitant methotrexate, 10-25mg once weekly either orally or parenterally. The anticipated time on study treatment is 2+ years, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>adult patients &gt;=18 years of age; RA for &gt;=6 months; receiving outpatient treatment; inadequate response to methotrexate, having received and tolerated it for &gt;=12 weeks, with a stable dose for &gt;=4 weeks. rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA; inflammatory joint disease other than RA, or other systemic autoimmune disorder; diagnosis of juvenile arthritis, or RA before the age of 16; previous treatment with &gt;1 biologic agent, any celldepleting therapies, or concurrent treatment with any biologic agent or DMARD other than methotrexate.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>